Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients

• Conditions: Ventilator Associated Pneumonia; Corona Virus Infection

• Registration Number: NCT04372576
• Lead Sponsor: Semmelweis University

Brief Summary

The aim of this study is to determine the risk factors for development of ventilator-associated pneumonia (VAP) and to identify the prognostic factors of VAP among Coronavirus Disease 2019 (CoViD-19) patients. We hypothesized that CoViD-19 serves as a high risk factor for the development of VAP and it affects clinical outcome measures negatively.

Detailed Description

Coronavirus Disease 2019 (CoViD-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic affecting thousands of individuals worldwide. A considerable proportion of CoViD-19 patients require admission to the intensive care unit (ICU), although limited data are available on their clinical characteristics and course. The results of retrospective studies indicate older age, presence of comorbidies and secondary infections as predictors of mortality among this population. Further evaluation regarding ICU clinical course and predictors of mortality is needed.

The aim of this study is to determine the risk factors for development of VAP and to identify the prognostic factors of VAP among CoViD-19 patients.

Study Timeline

• Status Verified: 2020-04
• Study Start: 2020-04-16
• Study First Submitted: 2020-04-29
• Study First Submitted QC: 2020-04-30
• Last Update Submitted: 2020-04-30
• Study First Posted: 2020-05-04
• Last Update Posted: 2020-05-04
• Primary Completion: 2020-08
• Study Completion: 2020-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Critically ill individuals diagnosed with PCR confirmed CoViD-19 disease
• Started mechanical ventilation for > 48 hours
• Informed consent signed by the patient or authorised representative

Exclusion Criteria

• Participation in an interventional trial aiming nosocomial infections
• refused informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28-day all-cause mortality	at study completion, anticipated 5 months

Secondary Outcome Measures

Name	Time	Method
ICU length-of-stay	average time frame expected 3-4 weeks
Antibiotic utilization	average time frame expected 3-4 weeks (at discharge from ICU)
Ventilator-associated pneumonia rate	at study completion, anticipated 5 months
Days of mechanical ventilation	average time frame expected 2-3 weeks

Trial Locations

Locations (1)

Semmelweis University; 🇭🇺 Budapest, Hungary